Drugs / rF1V vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00332956 Comparator | May 2006 → Feb 2008 | — | DynPort Vaccine Company LLC, A GDIT Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rF1V vaccine | “rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182” NCT00332956 ↗ |
| Known as | Recombinant Plague Vaccine rF1V | “Recombinant Plague Vaccine rF1V” NCT00332956 ↗ |
| Modality | Vaccine | “Recombinant Plague Vaccine rF1V” NCT00332956 ↗ |
| Route | Intramuscular | “intramuscular (IM) injection into the arm” NCT00332956 ↗ |